The viability of LOXL2 as an excellent diagnostic marker and a potential therapeutic target for HCC has previously been identified by Wong et al. HCC tissue presents higher expression levels of mRNA and immunoactivity of LOXL2 than that of non-tumor tissue. The gene discussed is LOXL2; the disease is hepatocellular carcinoma.